{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:45:07Z","timestamp":1793270707696,"version":"4.5.0"},"reference-count":138,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Fabry disease (FD) is a lysosomal storage disorder caused by deficient alpha-galactosidase A activity in the lysosome due to mutations in the GLA gene, resulting in gradual accumulation of globotriaosylceramide and other derivatives in different tissues. Substrate accumulation promotes different pathogenic mechanisms in which several mediators could be implicated, inducing multiorgan lesions, mainly in the kidney, heart and nervous system, resulting in clinical manifestations of the disease. Enzyme replacement therapy was shown to delay disease progression, mainly if initiated early. However, a diagnosis in the early stages represents a clinical challenge, especially in patients with a non-classic phenotype, which prompts the search for biomarkers that help detect and predict the evolution of the disease. We have reviewed the mediators involved in different pathogenic mechanisms that were studied as potential biomarkers and can be easily incorporated into clinical practice. Some accumulation biomarkers seem to be useful to detect non-classic forms of the disease and could even improve diagnosis of female patients. The combination of such biomarkers with some response biomarkers, may be useful for early detection of organ injury. The incorporation of some biomarkers into clinical practice may increase the capacity of detection compared to that currently obtained with the established diagnostic markers and provide more information on the progression and prognosis of the disease.<\/jats:p>","DOI":"10.3390\/jcm10081664","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T10:58:07Z","timestamp":1618311487000},"page":"1664","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up"],"prefix":"10.3390","volume":"10","author":[{"given":"Clara","family":"Carnicer-C\u00e1ceres","sequence":"first","affiliation":[{"name":"Laboratory of Inborn Errors of Metabolism, Laboratoris Cl\u00ednics, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Arranz-Amo","sequence":"additional","affiliation":[{"name":"Laboratory of Inborn Errors of Metabolism, Laboratoris Cl\u00ednics, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cea-Arestin","sequence":"additional","affiliation":[{"name":"Laboratory of Inborn Errors of Metabolism, Laboratoris Cl\u00ednics, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2359-3238","authenticated-orcid":false,"given":"Maria","family":"Camprodon-Gomez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"},{"name":"Unit of Hereditary Metabolic Disorders, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9777-7796","authenticated-orcid":false,"given":"David","family":"Moreno-Martinez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"},{"name":"Unit of Hereditary Metabolic Disorders, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"},{"name":"Lysosomal Storage Disorders Unit, Royal Free Hospital NHS Foundation Trust and University College London, London WC1E 6BT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lucas-Del-Pozo","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Laboratory, Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"},{"name":"Department of Neurology, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"},{"name":"Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6364-4570","authenticated-orcid":false,"given":"Marc","family":"Molt\u00f3-Abad","sequence":"additional","affiliation":[{"name":"Functional Validation &amp; Preclinical Research, Drug Delivery &amp; Targeting Group, CIBIM-Nanomedicine, Vall d\u2019Hebron Institut de Recerca (VHIR), Universitat Aut\u00f2noma de Barcelona (UAB), 08035 Barcelona, Spain"},{"name":"Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-0065","authenticated-orcid":false,"given":"Ariadna","family":"Tigri-Santi\u00f1a","sequence":"additional","affiliation":[{"name":"Unit of Hereditary Metabolic Disorders, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-6834","authenticated-orcid":false,"given":"Irene","family":"Agraz-Pamplona","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F","family":"Rodriguez-Palomares","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hern\u00e1ndez-Vara","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Laboratory, Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"},{"name":"Department of Neurology, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8294-6566","authenticated-orcid":false,"given":"Mar","family":"Armengol-Bellapart","sequence":"additional","affiliation":[{"name":"Neurodegenerative Diseases Laboratory, Vall d\u2019Hebron Institut de Recerca (VHIR), Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"},{"name":"Department of Neurology, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"del-Toro-Riera","sequence":"additional","affiliation":[{"name":"Unit of Hereditary Metabolic Disorders, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"},{"name":"Department of Pediatric Neurology, Unit of Hereditary Metabolic Disorders, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2386","authenticated-orcid":false,"given":"Guillem","family":"Pintos-Morell","sequence":"additional","affiliation":[{"name":"Unit of Hereditary Metabolic Disorders, Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Hospital Universitari, Passeig Vall d\u2019Hebron 119-129, 08035 Barcelona, Spain"},{"name":"Functional Validation &amp; Preclinical Research, Drug Delivery &amp; Targeting Group, CIBIM-Nanomedicine, Vall d\u2019Hebron Institut de Recerca (VHIR), Universitat Aut\u00f2noma de Barcelona (UAB), 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"ref_1","unstructured":"Adam, M.P., Ardinger, H.H., and Pagon, R.A. (1993\u20132021). Fabry Disease. GeneReviews\u00ae [Internet], University of Washington. [Updated 5 January 2017]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.rce.2017.06.007","article-title":"Fisiopatolog\u00eda de la enfermedad de Fabry","volume":"218","year":"2018","journal-title":"Rev. Clin. Esp."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Weidemann, F., Sanchez-Ni\u00f1o, M.D., Politei, J., Oliveira, J.P., Wanner, C., Warnock, D.G., and Ortiz, A. (2013). Fibrosis: A key feature of Fabry disease with potential therapeutic implications. Orphanet J. Rare Dis., 8.","DOI":"10.1186\/1750-1172-8-116"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"J. Am. Med. Assoc."},{"key":"ref_5","unstructured":"Metha, A., Beck, M., and Sunder-Plassmaann, G. (2006). Epidemiology of lysosomal storage diseases: An overview. Fabry Disease: Perspectives from 5 Years of FOS [Internet], Oxford PharmaGenesis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cca.2014.01.030","article-title":"Detecting multiple lysosomal storage diseases by tandem mass spectrometry\u2014A national newborn screening program in Taiwan","volume":"431","author":"Liao","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2119\/molmed.2012.00002","article-title":"Fabry disease: Incidence of the common later-onset \u03b1-galactosidase A IVS4 + 919G\u2192A mutation in Taiwanese newborns\u2014Superiority of DNA-based to enzyme-based newborn screening for common mutations","volume":"18","author":"Chien","year":"2012","journal-title":"Mol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_12","first-page":"3733","article-title":"Clinical significance of plasma globotriaosylsphingosine levels in chinese patients with fabry disease","volume":"15","author":"Ouyang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and Efficacy of Recombinant Human \u03b1-Galactosidase A Replacement Therapy in Fabry\u2019s Disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Najafian, B., T\u00f8ndel, C., Svarstad, E., Sokolovkiy, A., Smith, K., and Mauer, M. (2016). One year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in Male adult patients with Fabry disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0152812"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy. Evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.112.195685","article-title":"Vascular aspects of fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine","volume":"60","author":"Rombach","year":"2012","journal-title":"Hypertension"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1651-2227.2006.tb02392.x","article-title":"Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease","volume":"95","author":"Barbey","year":"2006","journal-title":"Acta Paediatr. Int. J. Paediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"Vasculopathy in patients with Fabry disease: Current controversies and research directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.2013.520","article-title":"Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease","volume":"86","author":"Shu","year":"2014","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-006-0340-x","article-title":"Structural and functional changes in peripheral vasculature of Fabry patients","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_29","first-page":"295","article-title":"Non invasive evaluation of endothelial function in patients with Anderson-Fabry disease","volume":"24","author":"Puccio","year":"2005","journal-title":"Int. Angiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10545-005-0563-2","article-title":"Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease","volume":"28","author":"Kalliokoski","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Dimitrow, P.P., Krzanowski, M., and Undas, A. (2005). Reduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic Doppler echocardiography. Cardiovasc. Ultrasound, 3.","DOI":"10.1186\/1476-7120-3-11"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.kint.2018.08.033","article-title":"\u03b1-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease","volume":"95","author":"Kang","year":"2019","journal-title":"Kidney Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3727\/096368916X694265","article-title":"Imbalanced production of reactive oxygen species and mitochondrial antioxidant SOD2 in fabry disease-specific human induced pluripotent stem cell-differentiated vascular endothelial cells","volume":"26","author":"Tseng","year":"2017","journal-title":"Cell Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Do, H.S., Park, S.W., Im, I., Seo, D., Yoo, H.W., Go, H., Kim, Y.H., Koh, G.Y., Lee, B.H., and Han, Y.M. (2020). Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells. EBioMedicine, 52.","DOI":"10.1016\/j.ebiom.2020.102633"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/ATVBAHA.113.302200","article-title":"Globotriaosylceramide induces lysosomal degradation of endothelial K Ca3.1 in fabry disease","volume":"34","author":"Choi","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/cvr\/cvq333","article-title":"Globotriaosylceramide leads to KCa3.1 channel dysfunction: A new insight into endothelial dysfunction in Fabry disease","volume":"89","author":"Park","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/8904_2014_371","article-title":"Innate and adaptive immune response in fabry disease","volume":"22","author":"Mauhin","year":"2015","journal-title":"JIMD Rep."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ivanova, M.M., Changsila, E., Iaonou, C., and Goker-Alpan, O. (2019). Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210617"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1681\/ASN.2008070694","article-title":"Lipid-protein interactions along the slit diaphragm of podocytes","volume":"20","author":"Schermer","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: Implications for Fabry nephropathy","volume":"26","author":"Sanz","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Liebau, M.C., Braun, F., H\u00f6pker, K., Weitbrecht, C., Bartels, V., M\u00fcller, R.U., Brodesser, S., Saleem, M.A., Benzing, T., and Schermer, B. (2013). Dysregulated Autophagy Contributes to Podocyte Damage in Fabry\u2019s Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063506"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of globotriaosylceramide in podocytes in fabry nephropathy is associated with progressive podocyte loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.ASN.0000016684.07368.75","article-title":"Renal pathology in Fabry disease","volume":"13","author":"Alroy","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2019.10.010","article-title":"Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis","volume":"129","author":"Rozenfeld","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev.iy.11.040193.001203","article-title":"The role of the CD28 receptor during T cell responses to antigen","volume":"11","author":"Linsley","year":"1993","journal-title":"Annu. Rev. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1681\/ASN.2013050518","article-title":"Role of podocyte B7-1 in diabetic nephropathy","volume":"25","author":"Fiorina","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1523-1755.2004.00477.x","article-title":"Clinical significance of costimulatory molecules CD80\/CD86 expression in IgA nephropathy","volume":"65","author":"Wu","year":"2004","journal-title":"Kidney Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1872214809666150302104542","article-title":"Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down","volume":"9","author":"Trimarchi","year":"2015","journal-title":"Recent Pat. Endocr. Metab. Immune Drug Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000045921","article-title":"Transforming growth factor-\u03b21 and myofibroblasts: A potential pathway towards renal scarring in human glomerular disease","volume":"87","author":"Goumenos","year":"2001","journal-title":"Nephron"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1042\/CS20120252","article-title":"Role of the TGF-\u03b2\/BMP-7\/Smad pathways in renal diseases","volume":"124","author":"Meng","year":"2013","journal-title":"Clin. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1681\/ASN.2010080793","article-title":"Mechanisms of tubulointerstitial fibrosis","volume":"21","author":"Zeisberg","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","article-title":"Possible role of transforming growth factor-\u03b21 and vascular endothelial growth factor in Fabry disease nephropathy","volume":"30","author":"Lee","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Jeon, Y.J., Jung, N., Park, J.W., Park, H.Y., and Jung, S.C. (2015). Epithelial-mesenchymal transition in kidney tubular epithelial cells induced by globotriaosylsphingosine and globotriaosylceramide. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136442"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"F1015","DOI":"10.1152\/ajprenal.00283.2016","article-title":"Characterization and phosphoproteomic analysis of a human immortalized podocyte model of fabry disease generated using CRISPR\/CAS9 technology","volume":"311","author":"Pereira","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/nep.12977","article-title":"Globotriaosylsphingosine induces oxidative DNA damage in cultured kidney cells","volume":"22","author":"Biancini","year":"2017","journal-title":"Nephrology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00041552-199911000-00001","article-title":"Nephropathic nature of proteinuria","volume":"8","author":"Remuzzi","year":"1999","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.carpath.2009.05.003","article-title":"A detailed pathologic examination of heart tissue from three older patients with Anderson\u2014Fabry disease on enzyme replacement therapy","volume":"19","author":"Sheppard","year":"2010","journal-title":"Cardiovasc. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"87161","DOI":"10.18632\/oncotarget.13552","article-title":"Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4 + 919 G > A mutation","volume":"7","author":"Chien","year":"2016","journal-title":"Oncotarget"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s10753-015-0214-1","article-title":"Elevated Endomyocardial Biopsy Macrophage-Related Markers in Intractable Myocardial Diseases","volume":"38","author":"Hayashi","year":"2015","journal-title":"Inflammation"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.humpath.2015.07.017","article-title":"Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy","volume":"46","author":"Chimenti","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","article-title":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: Results from the SOPHIA study","volume":"126","author":"Weidemann","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehp387","article-title":"Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease","volume":"31","author":"Brakch","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Song, H.Y., Chien, C.S., Yarmishyn, A.A., Chou, S.J., Yang, Y.P., Wang, M.L., Wang, C.Y., Leu, H.B., Yu, W.C., and Chang, Y.L. (2019). Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy. Cells, 8.","DOI":"10.3390\/cells8040327"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1221.e1","DOI":"10.1016\/j.cjca.2015.10.033","article-title":"Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy With Enzyme Replacement Therapy","volume":"32","author":"Chen","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e008424","DOI":"10.1161\/CIRCIMAGING.118.008424","article-title":"Predictors of Clinical Evolution in Prehypertrophic Fabry Disease","volume":"12","author":"Camporeale","year":"2019","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2014Role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2215\/CJN.06090809","article-title":"Biomarkers of Fabry disease nephropathy","volume":"5","author":"Schiffmann","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2007","journal-title":"Acta Paediatr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1515\/cclm-2016-0340","article-title":"Diagnosis of sphingolipidoses: A new simultaneous measurement of lysosphingolipids by LC-MS\/MS","volume":"55","author":"Polo","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Pettazzoni, M., Froissart, R., Pagan, C., Vanier, M.T., Ruet, S., Latour, P., Guffon, N., Fouilhoux, A., Germain, D.P., and Levade, T. (2017). LC-MS\/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: A novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181700"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes lyso-gb3 defines fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Ntwari","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Duro, G., Zizzo, C., Cammarata, G., Burlina, A., Burlina, A., Polo, G., Scalia, S., Oliveri, R., Sciarrino, S., and Francofonte, D. (2018). Mutations in the GLA gene and LysoGb3: Is it really Anderson-Fabry disease?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123726"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Yogasundaram, H., Nikhanj, A., Putko, B.N., Boutin, M., Jain-Ghai, S., Khan, A., Auray-Blais, C., West, M.L., and Oudit, G.Y. (2018). Elevated inflammatory plasma biomarkers in patients with fabry disease: A critical link to heart failure with preserved ejection fraction. J. Am. Heart Assoc., 7.","DOI":"10.1161\/JAHA.118.009098"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2019.10.031","article-title":"\u03b1-Galactosidase A\/lysoGb3 ratio as a potential marker for Fabry disease in females","volume":"501","author":"Baydakova","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"Rombach","year":"2011","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Rombach, S.M., Aerts, J.M.F.G., Poorthuis, B.J.H.M., Groener, J.E.M., Donker-Koopman, W., Hendriks, E., Mirzaian, M., Kuiper, S., Wijburg, F.A., and Hollak, C.E.M. (2012). Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047805"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"Boutin","year":"2012","journal-title":"Anal. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/092986713804806685","article-title":"A Metabolomic Study Reveals Novel Plasma Lyso-Gb3 Analogs As Fabry Disease Biomarkers","volume":"20","author":"Dupont","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1021\/ac401542k","article-title":"A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of fabry disease patients","volume":"85","author":"Manwaring","year":"2013","journal-title":"Anal. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13361-014-1060-3","article-title":"Metabolomic discovery of novel urinary galabiosylceramide\u2208analogs as Fabry disease biomarkers","volume":"26","author":"Boutin","year":"2015","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb 3-related analogues in fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/ac303033v","article-title":"Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for fabry disease by tandem mass spectrometry","volume":"85","author":"Lavoie","year":"2013","journal-title":"Anal. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cca.2015.06.003","article-title":"Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma","volume":"447","author":"Ferreira","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cca.2014.08.002","article-title":"Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry","volume":"438","author":"Blais","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cca.2019.10.005","article-title":"The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease","volume":"500","author":"Alharbi","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2017.01.018","article-title":"Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation","volume":"466","author":"Lavoie","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.bbadis.2019.07.005","article-title":"Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients","volume":"1865","author":"Heywood","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"13382","DOI":"10.1021\/acs.analchem.7b03609","article-title":"Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS\/MS in Urine of Fabry Disease Patients","volume":"89","author":"Boutin","year":"2017","journal-title":"Anal. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cca.2015.11.018","article-title":"Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients","volume":"452","author":"Abaoui","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ki.2008.576","article-title":"Downregulation of \u03b1-galactosidase A upregulates CD77: Functional impact for Fabry nephropathy","volume":"75","author":"Thomaidis","year":"2009","journal-title":"Kidney Int."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/joim.12801","article-title":"Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease","volume":"284","author":"Henkel","year":"2018","journal-title":"J. Intern. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1590\/2175-8239-jbn-3910","article-title":"CD77 levels over enzyme replacement treatment in Fabry Disease Family (V269M)","volume":"40","author":"Pereira","year":"2018","journal-title":"J. Bras. Nefrol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: Role of globotriaosylceramide","volume":"109","author":"Mucci","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy","volume":"1822","author":"Biancini","year":"2012","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1212\/01.wnl.0000247278.88077.09","article-title":"Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease","volume":"67","author":"Kaneski","year":"2006","journal-title":"Neurology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cca.2016.07.016","article-title":"Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy","volume":"461","author":"Biancini","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Carpio","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Trimarchi, H., Canzonieri, R., Schiel, A., Costales-Collaguazo, C., Politei, J., Stern, A., Paulero, M., Rengel, T., Andrews, J., and Forrester, M. (2016). Increased urinary CD80 excretion and podocyturia in Fabry disease. J. Transl. Med., 14.","DOI":"10.1186\/s12967-016-1049-8"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Trimarchi, H., Canzonieri, R., Schiel, A., Politei, J., Costales-Collaguazo, C., Stern, A., Paulero, M., Rengel, T., Vali\u00f1o-Rivas, L., and Forrester, M. (2017). Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease. Int. J. Nephrol., 2017.","DOI":"10.1155\/2017\/1287289"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nm1696","article-title":"Modification of kidney barrier function by the urokinase receptor","volume":"14","author":"Wei","year":"2008","journal-title":"Nat. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/257628","article-title":"Copious Podocyturia without Proteinuria and with Normal Renal Function in a Young Adult with Fabry Disease","volume":"2015","author":"Trimarchi","year":"2015","journal-title":"Case Rep. Nephrol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Fall, B., Scott, C.R., Mauer, M., Shankland, S., Pippin, J., Jefferson, J.A., Wallace, E., Warnock, D., and Najafian, B. (2016). Urinary podocyte loss is increased in patients with fabry disease and correlates with clinical severity of fabry nephropathy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168346"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40620-016-0271-z","article-title":"Podocyturia is significantly elevated in untreated vs. treated Fabry adult patients","volume":"29","author":"Trimarchi","year":"2016","journal-title":"J. Nephrol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5527\/wjn.v6.i5.221","article-title":"Podocyturia: Potential applications and current limitations","volume":"6","author":"Trimarchi","year":"2017","journal-title":"World J. Nephrol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00441-017-2630-z","article-title":"Quantifying podocyte depletion: Theoretical and practical considerations","volume":"369","author":"Puelles","year":"2017","journal-title":"Cell Tissue Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.1021\/acs.analchem.7b00858","article-title":"Absolute Protein Quantification by Mass Spectrometry: Not as Simple as Advertised","volume":"89","author":"Shuford","year":"2017","journal-title":"Anal. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cca.2019.03.1615","article-title":"Tandem mass spectrometry analysis of urinary podocalyxin and podocin in the investigation of podocyturia in women with preeclampsia and Fabry disease patients","volume":"495","author":"Martineau","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2020.10.006","article-title":"Proteomics for the study of new biomarkers in Fabry disease: State of the art","volume":"132","author":"Rossi","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1021\/pr301200e","article-title":"The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: Evidence of presymptomatic kidney disease in pediatric fabry and type-I diabetic patients","volume":"12","author":"Manwaring","year":"2013","journal-title":"J. Proteome Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3109\/0886022X.2010.516859","article-title":"Study of urinary proteomes in Anderson-Fabry disease","volume":"32","author":"Zima","year":"2010","journal-title":"Ren. Fail."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1039\/C4MB00707G","article-title":"Early markers of Fabry disease revealed by proteomics","volume":"11","author":"Matafora","year":"2015","journal-title":"Mol. Biosyst."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s10545-008-0900-3","article-title":"Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy","volume":"31","author":"Elleder","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jmedgenet-2019-106030","article-title":"Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease","volume":"57","author":"Doykov","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1006\/jmcc.2001.1433","article-title":"EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes","volume":"33","author":"Robert","year":"2001","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2119\/molmed.2014.00034","article-title":"Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure","volume":"20","author":"Mezzaroma","year":"2014","journal-title":"Mol. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bbrc.2017.03.030","article-title":"Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy","volume":"486","author":"Chen","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10545-006-0360-6","article-title":"Extracellular matrix turnover and disease severity in Anderson-Fabry disease","volume":"30","author":"Shah","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Loso, J., Lund, N., Avanesov, M., Muschol, N., Lezius, S., Cordts, K., Schwedhelm, E., and Patten, M. (2018). Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy. Front. Cardiovasc. Med., 5.","DOI":"10.3389\/fcvm.2018.00108"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in fabry disease","volume":"114","author":"Niemann","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Aguiar, P., Azevedo, O., Pinto, R., Marino, J., Cardoso, C., Sousa, N., Cunha, D., Hughes, D., and Soares, J.L.D. (2018). Biomarkers of myocardial fibrosis: Revealing the natural history of fibrogenesis in Fabry disease cardiomyopathy. J. Am. Heart Assoc., 7.","DOI":"10.1161\/JAHA.117.007124"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1161\/CIRCIMAGING.112.976738","article-title":"Myocardial tissue characterization using magnetic resonance noncontrast T1 mapping in hypertrophic and dilated cardiomyopathy","volume":"5","author":"Dass","year":"2012","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/jmri.24727","article-title":"Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload","volume":"41","author":"Sado","year":"2015","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jcmg.2013.03.008","article-title":"T1 Mapping for the diagnosis of acute myocarditis using CMR: Comparison to T2-Weighted and late gadolinium enhanced imaging","volume":"6","author":"Ferreira","year":"2013","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.jcmg.2015.11.014","article-title":"Myocardial T2 Mapping Increases Noninvasive Diagnostic Accuracy for Biopsy-Proven Myocarditis","volume":"9","author":"Spieker","year":"2016","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2016.02.013","article-title":"Comprehensive Cardiac Magnetic Resonance Imaging in Patients with Suspected Myocarditis the MyoRacer-Trial","volume":"67","author":"Lurz","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Bohnen, S., Radunski, U.K., Lund, G.K., Kandolf, R., Stehning, C., Schnackenburg, B., Adam, G., Blankenberg, S., and Muellerleile, K. (2015). Performance of T1 and T2 Mapping Cardiovascular Magnetic Resonance to Detect Active Myocarditis in Patients with Recent-Onset Heart Failure. Circ. Cardiovasc. Imaging, 8.","DOI":"10.1161\/CIRCIMAGING.114.003073"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ehjci\/jex230","article-title":"T2 mapping cardiovascular magnetic resonance identifies the presence of myocardial inflammation in patients with dilated cardiomyopathy as compared to endomyocardial biopsy","volume":"19","author":"Spieker","year":"2018","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1055\/a-0836-2723","article-title":"Assessment of Cardiac Involvement in Fabry Disease (FD) with Native T1 Mapping","volume":"191","author":"Roller","year":"2019","journal-title":"RoFo"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jacc.2016.07.741","article-title":"Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory Cardiomyopathy","volume":"68","author":"Nordin","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00259-015-3036-3","article-title":"First experience of simultaneous PET\/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease","volume":"42","author":"Nappi","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/8\/1664\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:47:33Z","timestamp":1760161653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/8\/1664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":138,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["jcm10081664"],"URL":"https:\/\/doi.org\/10.3390\/jcm10081664","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]}}}